多发性硬化患者使用钆特酸葡甲胺对齿状核和苍白球信号强度无影响
该回顾性研究纳入232例曾多次接受0.1 mmol/kg钆特酸葡甲胺静脉给药的多发性硬化患者,比较首次与末次T1加权图像上齿状核/脑桥中央及苍白球/半卵圆中心信号强度比值变化。结果齿状核/脑桥中央比值无显著变化,苍白球/半卵圆中心比值显著降低(p < 0.0001),但多变量分析显示钆剂注射次数与两比值变化均无显著相关。结论认为重复使用钆特酸葡甲胺未导致齿状核或苍白球T1信号强度增高。
要点
- 多发性硬化患者重复使用钆特酸葡甲胺后齿状核/脑桥中央T1信号比值无显著变化。
- 苍白球/半卵圆中心比值在首次与末次MRI间显著降低(p < 0.0001),但与注射次数无关。
- 多变量分析显示注射次数与齿状核/脑桥中央及苍白球/半卵圆中心信号比值变化均无显著相关。
核心结论
- 多发性硬化患者重复给予钆特酸葡甲胺未导致齿状核或苍白球T1信号强度增高;苍白球/半卵圆中心比值显著降低归因于MR参数变化而非钆沉积。
研究设计与样本
- 回顾性研究,纳入232例既往多次接受0.1 mmol/kg钆特酸葡甲胺静脉给药的多发性硬化患者,分析首次与末次非增强T1加权图像。
关键影像表现/征象
- 齿状核/脑桥中央T1信号强度比值在首次与末次MRI间无显著变化。
- 苍白球/半卵圆中心T1信号强度比值在首次与末次MRI间显著降低(p < 0.0001)。
诊断标准与关键数值
- 多变量分析控制年龄、病程及MRI间隔时间后,注射次数与齿状核/脑桥中央比值变化无显著相关(标准化beta = -0.018,p = 0.811)。
- 多变量分析控制年龄、病程及MRI间隔时间后,注射次数与苍白球/半卵圆中心比值变化无显著相关(标准化beta = -0.049,p = 0.499)。
临床应用与阅片要点
- 在报告多发性硬化患者增强MRI时,齿状核T1信号增高不应简单归因于钆特酸葡甲胺的重复使用。
- 苍白球/半卵圆中心T1信号比值降低需考虑MR参数变化的影响,而非钆沉积。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Previous studies on possible accumulation of gadolinium-based contrast agents (GBCA) in the brain suggest that macrocyclic GBCA are less likely to accumulate than linear GBCA. However, conflicting results have been reported, especially in MS. The aim of this study is to investigate retrospectively the correlation between gadoterate-meglumine (macrocyclic GBCA) use and T1 signal intensity changes (SI) in the dentate nucleus and the GP on unenhanced T1-weighted images in a large cohort of MS patients.
MATERIALS AND METHODS: Unenhanced T1-weighted images of 232 MS patients who previously received multiple intravenous administrations of 0.1 mmol/kg of gadoterate-meglumine were reviewed. The change in T1 SI ratios of dentate nucleus/central pons (DN/CP) and globus pallidus/centrum semiovale (GP/CSO) was calculated between the first and last MRIs and correlated with age, number of injections, time interval between MRIs, disease duration, activity, and therapy.
RESULTS: DN/CP ratio showed no significant changes whereas the GP/CSO ratio showed a significant decrease (p < 0.0001) between the first and last MRIs. Multivariable analyses of both ratios, controlling for age, disease duration, and time interval between MRIs, showed no significant correlation between the number of gadolinium injections and the differences in DN/CP (standardized beta = -0.018, p = 0.811) or GP/CSO SI ratios (standardized beta = -0.049, p = 0.499).
CONCLUSION: Repeated administration of gadoterate-meglumine in MS patients did not result in increased T1 SI in the DN or the GP. The significant decrease of GP/CSO ratio between the first and last MRIs is not due to gadolinium accumulation but rather to varying MR parameters.
引用
- Hannoun S, Issa R, El Ayoubi NK, et al. Gadoterate Meglumine Administration in Multiple Sclerosis has no Effect on the Dentate Nucleus and the Globus Pallidus Signal Intensities. Acad Radiol. 2018. PMID: 30527456. doi:10.1016/j.acra.2018.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。